NCT04634435View on ClinicalTrials.gov

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

January 10, 2025

Study Completion Date

January 10, 2025

Conditions
Multiple Myeloma
Interventions
COMBINATION_PRODUCT

BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2

Single dose infusion of BHV-1100 plus CIML NK Cells plus IVIG, followed by low dose IL-2

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

lead

Biohaven Pharmaceuticals, Inc.

INDUSTRY